Ophthalmology News and Research RSS Feed - Ophthalmology News and Research

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
PLXNA4 gene may increase risk of developing Alzheimer's disease

PLXNA4 gene may increase risk of developing Alzheimer's disease

Researchers from Boston University School of Medicine report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. [More]
Robert E. Marc named recipient of 2014 Paul Kayser International Award in Retina Research

Robert E. Marc named recipient of 2014 Paul Kayser International Award in Retina Research

Robert E. Marc, Ph.D., director of research at the University of Utah's John A. Moran Eye Center, has been named by the International Society of Eye Research as the recipient of the Houston, Texas-based Retina Research Foundation's 2014 Paul Kayser International Award in Retina Research. [More]
Early stage AMD can occur much earlier than previously thought

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries. [More]
Study shows correlation between education and nearsightedness

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted. [More]
Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision. [More]
Mount Sinai Hospital earns top rankings on the U.S. News & World Report's Best Hospitals Honor Roll

Mount Sinai Hospital earns top rankings on the U.S. News & World Report's Best Hospitals Honor Roll

By earning "top rankings" in six out of 16 medical specialties, The Mount Sinai Hospital achieved "Honor Roll" status in this year's U.S. News & World Report "Best Hospitals" guidebook. [More]
Advanced Cell Diagnostics’ in situ hybridization technology reaches two major milestones

Advanced Cell Diagnostics’ in situ hybridization technology reaches two major milestones

Advanced Cell Diagnostics Inc. (ACD), a leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced that its RNAscope® RNA in situ hybridization technology has reached two major milestones. In just three years, over 100 peer-reviewed papers featuring the technology have been published, and with the significant increase in use of RNAscope, ACD has now built a library of over 4000 target probes for numerous species. Probes are designed to order in under two weeks, and in just six months the library has grown by over 1500, reflecting the wide interest in ACD’s breakthrough technology. [More]
DARPins could revolutionize protein therapeutics

DARPins could revolutionize protein therapeutics

Integrating an INTEGRA VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners (Zurich, Switzerland) to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
Cataract surgery for people with dementia slows cognition decline, improves quality of life

Cataract surgery for people with dementia slows cognition decline, improves quality of life

Cataract surgery for people with Alzheimer's disease and other dementias not only improves vision but can slow decline in cognition and improve quality of life for both people with the disease and their caregivers, according to clinical trial results reported today at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen. [More]
New chemical compound protects against blindness and diabetes in animals

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. [More]
New approach for developing personalized gene therapies to treat retinitis pigmentosa

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. [More]
Integrated therapies can reduce depression by half among people with low vision due to AMD

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD). [More]
New approach can reduce depression in patients with AMD-related low vision

New approach can reduce depression in patients with AMD-related low vision

Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half. The study was funded by the National Eye Institute (NEI), part of the National Institutes of Health. [More]
Researchers discover a way to restore corneal surface

Researchers discover a way to restore corneal surface

A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye. [More]
Focal choroidal excavation’s coexistence with other choroidal diseases impairs vision

Focal choroidal excavation’s coexistence with other choroidal diseases impairs vision

Focal choroidal excavation appears to be relatively common and can have a detrimental effect on vision, a study of Korean patients suggests. [More]
Reticular drusen linked to AMD progression

Reticular drusen linked to AMD progression

Four percent of individuals aged 49 years and above will develop reticular drusen over 15 years of follow-up, Australian study findings suggest, with the incidence higher in those with age-related macular degeneration risk factors. [More]
Vitreous anatomic features characterised

Vitreous anatomic features characterised

Researchers have found a direct anteroposterior connection between the retrolental and premacular and preoptic spaces that exits in young adults before the occurrence of vitreous degeneration. [More]
BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma. [More]